Biotechnology company Tonix Pharmaceuticals has presented promising preclinical research for TNX-1700, its lead immuno-oncology candidate, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The research focused on a fusion protein version of TFF2 and its potential to improve cancer treatment strategies.
The preclinical data revealed significant advancements in targeting the tumor microenvironment. Researchers found that TNX-1700 could substantially reduce immunosuppressive neutrophils while simultaneously enhancing anti-tumor immune responses in gastric cancer models. The results were particularly notable when the treatment was combined with anti-PD1 therapy.
This research represents a critical step in developing more effective cancer treatments, specifically targeting gastric and colon cancers. By addressing the complex tumor microenvironment, Tonix is exploring innovative approaches to potentially improve patient outcomes and treatment efficacy.
The development of TNX-1700 is being pursued under a license from Columbia University, demonstrating the collaborative nature of advanced medical research. The findings suggest potential for more targeted and precise cancer therapies that could minimize the impact of immunosuppressive mechanisms within tumors.
